CERS - Earnings call transcript Q3 2017

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, ladies and gentlemen. And welcome to the Cerus Corporation Q3 2017 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time [Operator Instructions].

As a reminder, this conference call is being recorded today November 2, 2017. to Relations. host like Tim today’s now Investor Lee, would introduce for your conference, I

begin. may You

Tim Lee

today, Thank you, on Richard good Executive Kevin joined Obi operator, Green, and Cerus’ Officer; issued of Officer our release us everyone Benjamin, Moore, President to describing Greenman, also and Carol business Financial Chief for Medical today. who Vivek results thank XX, Cerus’ Jayaraman, With third announcing Commercial and Chief recent me highlights. Vice President and ended Regulatory the our a our Quality. the Cerus are afternoon. Chief call Chief I’d Senior Officer; our like Affairs the Dr. Officer; September Company’s press and financial quarter XXXX,

operating risks cash our activities announcement cerus.com. gross trials contracts, margin, expect differ and of program, cell regulatory-related and and These with site than and cause Company These including future other and Examples risks include statements that September this uncertainties temporarily risks to activity undertake no to and You make today’s U.S. future goals quarter related uncertainties during clinical make and on identified we the I’d forward-looking This in initiatives, cash, activities, and update be are and volume, to expenses, described sales, cell new statements to rather duty forward-looking customer to red some that guidance, could burn not Form this the forward-looking release statements today. future file our events, of and existing the and to at development in product to our access be XXXX, we or red product performance future product on foregoing site and with the and revenue under materially. and respect you could XX-Q We XXXX statements on product including events our sufficiency mix respect events contracts XX, cryoprecipitate, to the our Europe activities. will implementation, hospital statements performance commercial time. our press remind under and for will Web of copy obligation relate that of that events, commercial like we of results call facts a thereof, call launch historical statements. ended risk timing factors approval and are the Web involve will actual and forward-looking the updated potential shortly. in our any of archived

today, results Executive remarks from by call Kevin pleasure the introduce we’ll final opening remarks. have begin On with from from QX we’ll Chief President Cerus’ Officer. Greenman, Obi overview then and it’s will Obi financial conclude to the finally followed a And now, and Obi, my Vivek commercial

Obi Greenman

Good encouraged the joining afternoon. we today. commercially thank progress you development. And the by are for call Overall, and we both product in are making,

Spain; Germany; and have together in During EFS our announced one of reimbursement with in blood Italy, largest Madrid in announced the pathogen in the for tender our summer. this with two weeks, platelets reduced award we past for centers contract the partnership Kedrion national expanded

Europe significant operations gaining commercial are Our traction. in

illuminators to and France, working been blood the Since we’ve unlock Service European the at Germany July, Transfusion exceeded several in EFS diligently expectations. to French platelet implemented months, system. in progress we centers our all has key rapidly While the markets, and has during installed INTERCEPT last have

kits expanded platelet As have we begun of the a under agreement. efforts, result shipping these

Germany in believe compared With In reimbursement the during shelf Ehrlich for which contract Paul and should authorization XXX% ready reimbursement routine life waste and in large favorable conventional centers hospitals be approvals, platelets, the hand, receive blood soon marketing life their allows extended Institute. products Given experience shelf implement reduce as now German to at centers. from their at the period. INTERCEPT national with blood inactivation as Germany, incentives centers expired Diego. blood they U.S., extended month's past Meeting days hospital provide to with and INTERCEPT to saw INTERCEPT the have are distinct implement the at should platelets the or Pathogen of in the some in in EFS ability we place, for strong MAAs sentiment toward to In centers, customers. in their to conversion a shift AABB we confident use San INTERCEPT in last we

need adopt meeting, banks previous understood During reduction. blood with and the support. blood conversations specifics clinical year's technology reduction hospitals the At and encouragingly, revolved should pathogen into live around clearly center cause, dialogue to and of focus independent for however, AABB our integrate to became Meetings, this usually More operations. the potential their how customers the of their shared pathogen hospitals this shifted

for On the our forward ingredient for the product. Development to red the is red the cell assay of UPLC team new assay commercial on moving production scheduled. front, of development our make continues active as cell progress

the contract our of third, coming the of assay development method the I quarters; loss as testing development; one, We retesting to three release lab point on submission. in progress number will would secondly, and updates regular transferred we red UPLC CE and validation move our the But components. in the product commercial provide mark towards cell for the an to key anticipated validation; milestones

will to transfusing on our new submission major studies chosen thereby over the unmet greater for are significant expected regard control working Cerus directly INTERCEPT product clinical pathway allowing physicians, us the INTERCEPT commercial with for product. uptick of interface is a expediting allow opportunity to Cryo we required us addresses in and hospitals for need. cryoprecipitate, for model The the business the submission. we've that that PMA Finally, this

seen center million. to of we're results million our and blood in of and global France, Given we of XXXX Vivek on our our product million now year-to-date the tightening ramp compared update $XX commercial efforts. and in will guidance detailed the Italy previous and have provide our a understanding $XX the $XX million momentum to production Spain revenue U.S., our to to range guidance $XX

joined us As experience, you our as a let me with Officer it instrumental to extensive and refocusing skills and operations. have and over of And commercial Commercial know, has many his year been I'm over at someone Chief ago that, commercial with delighted in little shaping leadership Vivek to fortitude Cerus. turn Vivek.

Vivek Jayaraman

the events blood. to opportunities great you, can Thank Cerus. front market confidence time is of an compelling me Obi. we quarter the This and for us safer patient exciting of give in access that The expand meaningfully past

blood clinicians with in for Cerus encouraging. post-thaw offers is to product is and well have success many positioned of may transfusion products is and an Few key approximately go-to-market medicines size also Cryo approvals, and to INTERCEPT in pathogen intelligent be with this cell pairing for million. north reduced potential transfusion, approved of billion. companies $X we components. space in sight immediate is build is to aggregate Cerus segments an our first opportunities commercial Cryo, the red many and execution. today, have shelf to disciplined leader strategies mover participate categories, at create Furthermore, market opportunity Initial Key very from geographies. the extended undisputed potential in life our the market feedback the potential and So pioneer The line magnitude. which $X availability of pathogen with providing reduced for for soon

partnership ability deliver the has blood this execution, great Starting forward. centers, in with Our U.S., give gained confidence past valuable results close a deal we quarter to solid year. to going a of our the come knowledge in me and clinicians. past have with hospitals insight This

center and than interest-in We of care. are demand-for to the the about realities clinical efficiency also a make and customers, pathogen confident facing more reduction. better Furthermore, in are the INTERCEPT understand blood today ever smarter platelet gains our we required production standard

filed banks education their are hand-in-hand cross-functional and to includes closely receive marketing, with sales, operations. They Our raise they ensure product drive working ready deployment also and into hospital with which awareness. that to the are clinicians to blood integrate team, and to with hospitals working are affairs, INTERCEPT

our our yielded center units of During the significant blood the last has optimizing customer results. few months, pathogen reduced produced on number by focus

an As XX% the of treatable and implementing efforts by over Meeting, the collection show potential increase our process. study recent American could Red a by Cross for AABB manufacturing example, platelets to case percentage the the modification during that presented collaborative

other centers confident are a presented unique to U.S. we Instead, why platelets. ARC, similar we that are determining the a Accordingly, how that discussing on production. INTERCEPT longer of the centers optimize findings focus path they Beyond blood no to clear to adopt INTERCEPT are when clear their asking early to production should is optimize have there market. challenges INTERCEPT. ability Blood the addressing

clinical generate banks platelets. Encouragingly, administrators positioned Another to act It demand, response to many awareness initiative that enable production and stating an INTERCEPT. move create In sure this supply desire implementing is to INTERCEPT to increase a of are making and demand, supply them clinicians to INTERCEPT modifications blood for hospitals, are our clinicians. diligently balancing are to a to team field educate while well platelets. centers adoption XXX% of to transfusing blood is

for platelets to blood grow, As reduced are centers hospital pathogen urgencies supply. up demand to ramp moving continues increased with

compared from to to nine the results. up on BLAs XXXX, INTERCEPT a platelet country BLA the the to blood XXXX for XXXX. the sales U.S. of critical nine up manufacturing Through It’s basis. centers. center XX% are availability level components blood kit sequential kit for when compared months months sales hospital process first supply increasing location. at year-over-year activities nearly when U.S. XXX% XXXX. of shipment as were of the Our were up centralized generating and platelet both were and both around a of U.S. allow QX QX sales first

approval. Island receive we announced last month, their BLA As the first was Center to Blood Rhode

and is focus. BLA to University. the platelets supply the lines other a weeks at between places the state in With Yale connection to and QX. demand banks more Seven Rhode have made end, we clinical hand, months. available submitted encouraging tighter expected that process coming in in their from shipping we across main be like Driving BLAs, and blood approvals Island the to see our center continues To INTERCEPT hospital blood now

largest Europe. turning is the for exciting institute of announcement the step mentioned on excess significant up we the hospital our platelet France, InEK, continued German Now, which German $XX market to rumination big of is opening market a encouraging reimburse certainly in forward Obi reduced in and by is pathogen number Also million is Based to the Europe. This is March the believe platelets. recent in annually. that platelets development in produced, a opportunity news.

be significant our of allows German to is five up the blood German take in pathogen days now, XX% and our improvement time. to centers could overall to come. hospitals for In the storage logistics growth PI facilitate The years broadly to goal the the and key for store process mentioned, both German driver to submissions -- store a process four-day rate, are the The for platelets. expect market decrease combined platelets reimbursement the centers the and Right platelets Once German driver a EMEA implementation blood franchise. currently in confident where European to as should for conventional Obi will be for MAA usual platelet MAA for budgeting potential versus production. market. as our favorable by ability As PLT up market growth the blood and we makes to at the the completed, five-days discards reduced German centers us immediate term, reduction business platelets platelet that pathogen wastage high in

to of we centers a win CTCM. the a meaningful of in earlier the blood Spain. recently large tender in portfolio. CTCM our standards direct this countries. the evidence been the in and largest products we It award Madrid, Spain. We awarded in provides follow is to week, community the We see As customer or other believe were center one chose influential transfusion European contract INTERCEPT this established encouraging of value secured up is of announced for this

Italian with distribution agreement Kedrion. We also our announced new

fractionation. and Kedrion, with and blood manufacturer you distributor of familiar a expertise of with in plasma may products, be collection Some global

With deep agreement Italian be in will market all first on pathogen Europe anticipated has of we distribution manufacturer they're this key that of headquarters blood today when blood importance in Italy, they CE engaged plasma bring believe cells, a customer relationships components, in knowledge their and global receipts new three of standards plasma safety. and Italy. establish red defining of as mark also encompasses that is the derivatives, opportunity upon This to standard Realizing platelets instrumental in and the our INTERCEPT approval. reduction and Kedrion care in nationwide significant fully launched

a cusp as exciting tipping to These significantly INTERCEPT I adopt are the times. Europe on the forward of across across summary, we In standard care, a are moving countries safer patient expanding towards more As access believe that we continent. are blood. of point

am that expect Cerus today things about we impact and excess with financial in results over on this the to quarter. we excited deliver provides excites progress plans to results. growth. have technology to look billion to in market that line products, for me a forward I One the With quarters made platform in markets to healthcare let compelling We of positively review it and me of scale. soon right that, a to feel major in sustainable our $X perspective, the to drive in on top most that operate is $X continuing the of are turn people operate come our place I'll strong Cryo. past Kevin red come. in cells to inclusion that years of the commercial update the From commercial progress a you and meaningful billion confident in and to

Kevin Green

Thanks, X% derived the from increase from Vivek. recently year both $XX.X reported strong as a million well from completed an U.S., most earlier. from in the the we growth revenue platelet illuminator Earlier million, demand This quarter $XX.X in in product sales. and was EMEA of kits up reported as today,

sales the in Importantly, illuminator the France. of of majority early deployment were results

comparing XX% INTERCEPT XX% patterns today, As on providing Worldwide, demand Middle a for were kit Eastern all dollar or kit the ordering a been same illuminators the to in gains EFS offset EFS Those was we platelet to France up basis now ramp period. QX from speak a largely when foundation both distributors. plasma year decline and sites, as XXXX from to deployed prior result have by sales certain of production. a

quarter. margin the period. of than The in gross a sales. of the quarter The platelet kits margin mix the sales, also margin during cost With for XX% on relative platelet was plasma to the dominated the healthy growth platelet plasma of sales account This XX% the differential from platelet globally, than cost higher which kit compared our more now XX% most kits with by is margin kit by largely lower the cells year of was to margins revenue. product result have of recent kits. driven were revenue sales improvement contribution for product prior Gross

activities we operating the margins same $XX.X XX% initiatives, for in million to increased for also For Phase $XX.X sites driver quarter platelet red the enrolled prior study. most operating like quarterly the X have to had I’d period inventory primary overall to were expenses. completed more period. kits Total our were the compared to BARDA efficient compared for in cell platelet recently management. Throughout was XXXX, expenses with year-to-date for U.S. XX% of year year-to-date blood Similar prior our million and now for year. the results, turn the period, margins, the to a along higher improved the more proportion

quarter during improved call, our R&D of staff and second we utilization our BARDA have we the program. the clinical As on noted

BARDA R&D offset more As while is was revenue. as XX% which increased such, than reimbursement, spending government by that contract recorded by

BARDA realize to were development $X.XX Going higher the $XX.X $X.XX leverage forward, losses net to under BARDA losses third margins were million million million to infrastructure. cell $XX a prior for or share commercial the as million quarter we and from red diluted quarter build for the prior period. compared recent quarter increased SG&A year-over-year basis, from the the share contribution compared period. Completion compared for were continue of in $XX.X as the trend and a support prior period. to narrow elevated U.S. million year and red year operating expenses. revenue were Improved diluted development operating the net out Net help the begin On we or per team per million On commercial prior most year period. $XX this activities U.S. for over basis, blood year-to-date year-to-date during expect sales $XX.X the contributed to expenses clinical year-to-date to expenses continue losses $XX.X to contract flat efforts ramp. cell our the the reported year product

months September our which nine sold the gain. we of $X.X provided XXXX, XX, ended Aduro, During million holdings a

refinancing sheet. September June balance completed investments The recently the ended additional XX, million We capital. XX, compared million growth of at Looking us and at and our with with XX $XX million short-term cash approximately at capital $XX XXXX. facility provided to of $XX December XXXX

an as that, interest-only allowing work revenue gaining diligently France INTERCEPT to million rest to within you, facility in two introduce by growth well extended on capital, and growth care We Greenman the also which estimate towards are in making the commercial to gives of the than from Thank to And is turn global of that $XX This and coming of us the provides like close option from markets, Obi. now focus combined opportunity an space call Importantly, meet Germany. conviction the into build as greater the standard largest additional the represent to influential and period Europe's momentum to us over shift, paradigm two annually, medicine back on as transfusion beyond. EMEA, and progress are XXXX I’ll EU. those organization. inventory significant across the the markets growth ability U.S. our I an with would increasing We Kevin. for also Obi now we as we the business emphasizing an progress drive

towards of major number to U.S. We use. academic an INTERCEPT medical adoption market also of see the moving centers increasing routine with continue in

this cell readout INTERCEPT and still the evaluating more with SPARK FDA red with no blinded, To-date, completed the has in cells XX there've INTERCEPT anemia of been in anemia than the to endpoints in thalassemia towards are Phase We've study, patients the will this BARDA the supported expanding study by our a our well for study units program, in XX excited specific advancing with reached cells sites and for center blood RedeS X,XXX study enrolling critically is ReCePI study, U.S. red to EMEA patients We're assessing sites is Our that study. of transfused cell the about we detected INTERCEPT the XX in the while on are as in study cardiovascular afforded study, bleeding in at program the which that our INTERCEPT We're Cryo over working as with development U.S. importance transfusions. cells has repeated are the this QX. also INTERCEPT database agreement U.S.; transfusion transfusion patients. treated currently opportunities surgery in both and number antibodies lock be chronic its future red Phase increasingly patients. quarter anemia study And III acute in currently III red the manufacturing finally, chronic for red

market revenue availability believe blood drive in we programs the term medicine redefining and and for growth have field place measures near with we to transfusion our that pipeline, of are years. the that development confident Given we proactive safety concerns. opportunities more But addressing even our we for the coming importantly, are

both Before open would many U.S. for the abroad acknowledge in the the questions, contributions Cerus like employees, of we to call I and the

deployment It worldwide. the a support the fantastic great providing appreciation for done presentations this year’s at have and support acknowledged members the was by AABB Cerus heartfelt in customers see clinical customers and from this to broadly to team in the team. our job in many Meeting, our Our scientific

open important physicians. at Company mission for very on please have questions. We patients call team the that focused the a is Operator, here for and its great

Operator

And [Operator the comes our of Drew you from Stephens. Thank from first Jones line Instructions]. question

Your line is open. now

Drew Jones

going the I lines placements rate? is at there a look XQ to start wanted to stocking placed the there those that are it ramp when for referenced in that to run along what, And any capacity illuminator with full is sufficient from XQ. XQ, we there guys or getting you levels? France kits that and then Is handle

Obi Greenman

part that first of then turn it over Kevin. to and I'll question take the

So And need more answer the do I was think centers to EFS. install no. illuminators question your the regional any blood sites the nature at is of at they that question to the

use, production So kits they're for turn that to going implemented and over of Kevin. I'll to regard forward, routine are today. that fully in as are With needed routine

Kevin Green

I Yes, caveat. just one provide would and

all French period. all So the base sites understanding have as up. speak as over sites. our the the reported to in we’ve not But we today, were QX, mentioned, care illuminators INTERCEPT as been standard the make to plan, It’s deployed that

But the contract rollout think some the be I to that scheme XX technology large it's stocking they don’t may that know since there will period. where As a first orders. period. their ramp sites, is those be really certainly over There in we base

Drew Jones

BLA, domestically BLA And then total all capacity the a quick centers? that shifting to blood those just maybe the questions, facilities of couple seven what’s of pursuing for are aggregate in

Kevin Green

to think one answer other Red XX% chunk, order I There market. overall XX% the that on Yes. big -- so and the is can the XX%. precisely. I is systems the I think XX%, is another blood that’s But of of Cross, that’s of and don’t them obviously

those additional So of the the the of majority BLAs rest market. seven cover

Drew Jones

terms a sounds result last of hiccups like Puerto one me. as there of in And were no trails for Hurricanes? RBC then It Rico

Obi Greenman

Obviously, I’ll hospitals you Richard. and can to we down an on are are But turn where have give update there shut today? things over the generators to-date. Rich that been to as

Richard Benjamin

little a are blood communications for still as blood Rico trial. centers and manufacturing hospitals. and will the be Puerto on blood shutdown And by hospitals for our had general use, back-up center generators, was is our a devastated real three blood I guess, to import will The soon period. know, you are enrollment did The as back-up blood that at problem. they longer and making take a Hurricane the for

get working them are we them in as speak So to enrollment. we with backup

Does three I that to will mainland we sites on that we More producing importantly, enroll I recruit plan be center up believe, identified patients for And blood think bringing and on QX the mainland we QX. have red a that question? cells. have answer the in

Operator

from our Company. Thank you. Jennings the comes of from Josh And line question next Cowen and

now line Your is open.

Josh Jennings

successes the and just on guidance a ask in I quarter. could a update. just off that was you start the acceleration? on the little fourth was ramp give of in drivers Europe in hoping about us in the confidence recent the quarter there what’s And It I hoping range. to the implies Congrats and at XXXX the you top-line bit terms color give of of mid-point sequential nice the

Obi Greenman

So I going think, QX. obviously, to know shape quarter. going And growth, will the we going French is coming a growth important that online into for is lot support to forward. is entirety We believe that XXXX, going driver. is up of there drivers how be the to But strong be don’t an exactly of a going QX

Josh Jennings

we there the the France or quarter anything revenue well outside we anything as in should be number? as is that implied And U.S. considering of look at fourth

Obi Greenman

let handle one. that I’ll Kevin

Kevin Green

year the to, kit strong in as QX, prepared sales. was ramping Vivek’s definitely growth in nice there’s is alluded comments recall U.S. illuminator demand. U.S., last as you’ll Josh, by dominated

So we certain particular, have the very regions, forward, demand in kit distributor East. QX beyond the healthy. do expect that, be then strong will coming that Middle from And but going won't in fairly growth we

Obi Greenman

we're right growth countries. in multiple Josh, more now multiple And broadly, I seeing think in geographies

multiple there's year into to going So it's confident pull. that next leverage

Josh Jennings

update the out ramp, is mask AABB, And to that's issues in anything going up terms can at terms to of could Any play just update next incremental Cross quarter the in weighing you of the share? they there's come InterSol on manufacturing in rear the Red discussions in any plan American ramping view just see of any getting that for Red of how wanted be Cross I terms mirror, there manufacturings. [Biolon] them year. BLA your or in sites if Is American ramp new first with

Obi Greenman

how over sites focused I'll fundamentally from second. production turn what successfully you think use, evidenced that that do on AABB I routine and on his been with are was team what’s can hospital demand to the about that Meeting. really production last a been months I the I going the and to to But over give and those the is team we in Vivek with But have demand. Vivek But in three meet match ramp it think this Vivek t Red think Cross? specifics

Vivek Jayaraman

as plans of a to approval manufacturing we footprint and manufacturing they out one as presented AABB, at I mentioned their XX analysis and coming and noted indicated, and products. they those increasing weeks in Josh are where BLA months. and we Obi expand experience that INTERCEPT the They before, here the the as with pointed XX% correctly And know north shows sites currently ARC at sites is can their anticipate data their for that production INTERCEPT about get of production. their

in terms process actually they're So production. collections in increase adopting to of in those and manufacturing modifications allow for the

the by making. progress encouraged they're we're So that

partner and here able their of that find offer a so their INTERCEPT patients partner is hospitals future. to the them be our in be expectation near to good to continue platelets more We created

Josh Jennings

cryoprecipitate. last on then just question, INTERCEPT And

how timelines States we well? the that are for United lot. in the were you could PMA submission. terms in working approval guys You and a as outside U.S. about type of product potentially about thinking think of Any Thanks when

Obi Greenman

is XXXX and really stability going to the product completing the for coagulation of studies, focus be running factor the time then points. the So the in-vitro studies, final

So like. taking what would longer we that's than

to hold the just product have and different think you that. change time can't obviously the really points you for I stability

we've very especially patients, the outside environment. that and PMA I five of be that the several the month seen are there With trauma interested this thing other are would thought review day six and to use markets claim. Cryo, XXXX important critical U.S., in Cryo that the regard that roughly general, clock. of it's in think to Cryo submission the a just in are timeframe in interest Cryo to there because pre-hospital So shelf a label, life in factors bleeding label coagulation And for is seen be increasing are in lot

the think anticipated. the it of your driving of treatment other agent, [indiscernible] need in on XIII in we is interest specifically markets factors and that but factor recognition wouldn’t for [XX.XX] question? interest have did further -- Cryo I and that answer or increasing demand patients also early these the Josh,

Operator

next you. from line Emily Thank the Robert of from question And Baird. Stent comes our W.

Your now line is open.

Emily Stent

off, distribution week. First Italian the announced earlier agreement congrats on

you can in you Just how revenue you do curious how quickly think and ramp? generate do the distributor much can Italy, think

Kevin Green

with starting just We’re them.

partner market nice to understands INTERCEPT the product looking this is components they a that thing in standard think significant Italy. across Italy. care is to that are and all It’s as for of a blood I need very establish a really

X.X million cells, XXX,XXX XXX,XXX annually. plasma to red and think So doses roughly close units I annually platelet XXX,XXX roughly think to I

just there in is where so, because for today of And what strong roughly issue. in their because want the the But market, product think this million we their the week. use announced alone, with in the demand routine is hospitals annually. are of chikungunya platelets got on in don’t interest and agreement Rome million just speculate the the to $XX to Rome Italy just and as outbreak and they’ve been have for target late INTERCEPT, range are, ramping this $XX I in I obviously

Emily Stent

this you the of in you think and could And French and France level what generate quarter, year revenue in generate breakout much XXXX? can then do how revenue

Kevin Green

quarter. not being And contract going July, end for the new on the contract. at early the break of to it it’s out We’re obviously, the with signed

France. about annually transfused we as is doses platelet XXX,XXX there said, I think in

annual opportunity market roughly for us. so million $XX plus And that’s

we expect. at to production in just what sites. the so all when you’d routine get And that’s routine It’s

Obi Greenman

platelet demand say up I’d that the is just what was QX. QX slightly from Emily, French

we the move So time? really we’ll of effect this new as see contract in forward

Emily Stent

me. for one last And

in applying that approval Rhode incremental have the to are change So the way veterans producing? that after capacity first blood seen BLA seeing? get of month, for have demand the any in having BLAs fill that Did blood they’re customer that centers out Island last supply state

Obi Greenman

and have Connecticut see state-lines your have they shipping We’ll point. them aware that the in And we’re are across to customers elsewhere. already supplying and we on lateral seen products

blood today lack times from centers. I supply the probably we to So alternative is and an then think interstate across see exciting way some address that of we from in the this of have that shipments market

Operator

I’m over any at time. any questions, for remarks. turn to Obi not like further call would I this closing the to back Greenman showing now

Obi Greenman

joining Thank Cerus. your us in and for you all interest for today

forward conferences be investor two person that seeing will at look to you and later We month, we many presenting of in time. this at

be will you and very that we much. March in forwarding call Thanks QX Our look time. early at

Operator

conference. thank and Ladies day. in today’s a nice you disconnect. for have may you participating program the gentlemen, all conclude This Everyone, does and

Tim Lee	Investor Relations
Obi Greenman	President and Chief Executive Officer
Vivek Jayaraman	Chief Commercial Officer
Kevin Green	Chief Financial Officer
Richard Benjamin	Chief Medical Officer
Carol Moore	Senior Vice President of Regulatory Affairs and Quality
Drew Jones	Stephens Inc
Josh Jennings	Cowen and Company
Emily Stent	Robert W. Baird

Cerus (CERS) 2 Nov 172017 Q3 Earnings call transcript